CYCLOPHOSPHAMIDE | N217651 | BAXTER HEALTHCARE CORP
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 2 | Active | Sun Yat-sen University | 156 | 2019-01-10 → 2026-09-30 | |
| Phase 1/2 | Active | Diane George | 14 | 2013-06-03 → 2026-07 | |
| Phase 2 | Active | National Cancer Institute (NCI) | 70 | 2010-10-05 → 2028-10-31 | |
| Early Phase 1 | Active | Tatsuo Kawai, MD, PhD | 12 | 2025-05-31 → 2030-12-31 | |
| Phase 3 | Active | Celgene | 850 | 2024-06-19 → 2029-06-26 | |
| Phase 1 | Active | Roswell Park Cancer Institute | 9 | 2017-12-08 → 2032-03-23 | |
| Phase 2 | Active | M.D. Anderson Cancer Center | 88 | 2011-10-05 → 2027-10-31 | |
| Phase 1/2 | Active | Memorial Sloan Kettering Cancer Center | 113 | 2015-05 → 2027-04-30 | |
| Phase 1/2 | Active | M.D. Anderson Cancer Center | 15 | 2024-01-31 → 2029-01-01 | |
| Phase 2 | Active | Laura M. Spring, MD | 120 | 2020-12-16 → 2026-12-31 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$361.87
Highest Price
$721.76
FSS NDCs
2
Big4 NDCs
0
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 00338-9777-01CYCLOPHOSPHAMIDE 200MG/ML INJ,SOLN | $361.87 | FSS | Baxter Healthcare Corporation | 08/14/2026 |
| 00338-9779-01CYCLOPHOSPHAMIDE 200MG/ML INJ,SOLN | $721.76 | FSS | Baxter Healthcare Corporation | 08/14/2026 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
14 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Jun 28, 2023 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.
No patent or exclusivity listings for this strength.